Corteva (NYSE:CTVA) Announces Earnings Results

Corteva (NYSE:CTVA) posted its earnings results on Tuesday. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.32, Zacks reports. The business had revenue of $4.91 billion for the quarter, compared to analysts’ expectations of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.13 earnings per share. Corteva updated its FY 2026 guidance to 3.450-3.700 EPS.

Corteva Price Performance

Shares of CTVA opened at $81.09 on Friday. The company’s 50-day moving average is $80.68 and its 200-day moving average is $72.61. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.47 and a quick ratio of 0.96. The firm has a market capitalization of $54.24 billion, a PE ratio of 47.70, a PEG ratio of 2.77 and a beta of 0.59. Corteva has a fifty-two week low of $60.53 and a fifty-two week high of $85.63.

Corteva Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Monday, June 1st will be issued a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Monday, June 1st. Corteva’s payout ratio is currently 42.35%.

Insider Transactions at Corteva

In related news, insider Brian Titus sold 8,311 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the sale, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This trade represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.15% of the company’s stock.

Institutional Investors Weigh In On Corteva

A number of hedge funds have recently modified their holdings of the stock. Harris Associates L P lifted its position in shares of Corteva by 168.1% during the 4th quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock valued at $1,141,268,000 after buying an additional 10,675,052 shares during the last quarter. Amundi increased its holdings in Corteva by 125.3% in the 3rd quarter. Amundi now owns 3,415,554 shares of the company’s stock worth $219,620,000 after acquiring an additional 1,899,248 shares during the last quarter. Invesco Ltd. raised its stake in Corteva by 16.7% in the 4th quarter. Invesco Ltd. now owns 11,404,960 shares of the company’s stock valued at $764,474,000 after acquiring an additional 1,630,712 shares during the period. State Street Corp lifted its holdings in Corteva by 3.7% during the fourth quarter. State Street Corp now owns 36,570,876 shares of the company’s stock valued at $2,451,346,000 after purchasing an additional 1,290,071 shares during the last quarter. Finally, Man Group plc lifted its holdings in Corteva by 16,474.3% during the third quarter. Man Group plc now owns 1,294,125 shares of the company’s stock valued at $87,522,000 after purchasing an additional 1,286,317 shares during the last quarter. Institutional investors own 81.54% of the company’s stock.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Royal Bank of Canada raised Corteva’s price target to $97 from $95 and kept an outperform rating, signaling confidence in roughly 20% upside from recent levels. RBC Capital adjusts Corteva price target to $97 from $95, maintains outperform rating
• Positive Sentiment: Jefferies also increased its target on Corteva to $97 from $95, reinforcing a bullish view on the stock’s longer-term valuation. Jefferies adjusts price target on Corteva to $97 from $95
• Neutral Sentiment: UBS raised its target to $90 from $88 but kept a neutral rating, suggesting limited near-term conviction despite modest upside potential. UBS Group AG price target raise
• Neutral Sentiment: Citigroup lifted its target to $85 from $83 and maintained a neutral rating, indicating some valuation support but no strong bullish call. Citigroup Inc. price target raise
• Neutral Sentiment: Corteva said CEO Chuck Magro and CFO David Johnson will speak at the BMO Global Farm to Market Conference on May 14, a routine investor-relations event with limited immediate impact. Corteva to Participate in BMO Global Farm to Market Conference
• Neutral Sentiment: BNP Paribas Exane nudged its target higher to $77 from $74 but still implied downside from the stock’s recent trading range, making it a mixed signal. BNP Paribas adjusts price target on Corteva to $77 from $74

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group raised their price objective on shares of Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Oppenheimer increased their price target on Corteva from $86.00 to $89.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Royal Bank Of Canada raised their price target on Corteva from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Thursday. CICC Research upped their price objective on Corteva from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Finally, Zacks Research downgraded Corteva from a “strong-buy” rating to a “hold” rating in a report on Friday, February 20th. Thirteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.05.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.